

LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE {CARDBOARD BOX (20 ml, 50 ml, 100 ml and 250 ml bottle)}.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Inflacam 20 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 20 mg/ml

3. PACKAGE SIZE

20 ml
50 ml
100 ml
250 ml

4. TARGET SPECIES

Cattle, pigs and horses.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Cattle: s.c. or i.v. use.

Pigs: i.m. use.

Horses: i.v. use.

7. WITHDRAWAL PERIODS

Withdrawal periods:

Cattle: Meat and offal: 15 days; milk: 5 days.

Pigs: Meat and offal: 5 days.

Horses: Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 28 days, by ___ / ___ / ___

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

14. MARKETING AUTHORISATION NUMBERS

Vm 08749/5013

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE {BOTTLE (50, 100 ml and 250 ml)}.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Inflacam 20 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 20 mg/ml

3. TARGET SPECIES

Cattle, pigs and horses.

4. ROUTES OF ADMINISTRATION

Cattle: s.c. or i.v. use.

Pigs: i.m. use.

Horses: i.v. use.

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal periods:

Cattle: Meat and offal: 15 days; Milk: 5 days.

Pigs: Meat and offal: 5 days.

Horses: Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

6. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 28 days, by ___ / ___ / ___.

7. SPECIAL STORAGE PRECAUTIONS

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {BOTTLE (20 ml)}.

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Inflacam 

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Meloxicam 20 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Inflacam 20 mg/ml solution for injection for cattle, pigs and horses

2. Composition

Each ml contains:

Active substance

Meloxicam 20 mg

Excipient

Ethanol (96 %) 159.8 mg

A clear, yellow solution.

3. Target species

Cattle, pigs and horses.

4. Indications for use

Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

5. Contraindications

Do not use in horses less than 6 weeks of age.

Do not use in pregnant or lactating mares.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

See also section "Special warnings"- "Pregnancy and lactation".

6. Special warnings

Special precautions for safe use in the target species:

Treatment of calves with Inflacam 20 minutes before dehorning reduces post-operative pain. Inflacam alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain.

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use in pregnant or lactating mares.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

Overdose:

In case of overdose, symptomatic treatment should be initiated.

Major incompatibilities:

None known.

7. Adverse events

Cattle:

Common (more than 1 but less than 10 animals in 100 animals treated)	Injection site swelling ¹
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylactoid reaction ² .

¹Slight and transient following subcutaneous administration

²May be serious (including fatal). If such reaction occurs, it should be treated symptomatically.

Pigs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylactoid reaction ¹ .
--	---------------------------------------

¹May be serious (including fatal). If such reaction occurs, it should be treated symptomatically.

Horses:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylactoid reaction ¹ .
Undetermined frequency (cannot be estimated from the available data):	Injection site swelling ²

¹May be serious (including fatal). If such reaction occurs, it should be treated symptomatically.

²Transient, that resolves without intervention.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Subcutaneous use (cattle).
Intramuscular use (pigs).
Intravenous use (cattle, horses).

Cattle

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

Pigs

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

Horses

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).

For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculo-skeletal disorders, Inflacam 15 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection.

9. Advice on correct administration

Avoid introduction of contamination during use.
To ensure a correct dosage, body weight should be determined as accurately as possible.
The use of suitably calibrated measuring equipment is recommended.

10. Withdrawal periods

Cattle: Meat and offal: 15 days; milk: 5 days.

Pigs: Meat and offal: 5 days.

Horses: Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 08749/5013.

Pack sizes:

Cardboard box with one 20 ml, 50 ml, 100 ml or 250 ml vial.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:

Chanelle Pharmaceuticals Manufacturing Ltd
Loughrea
Co. Galway
Ireland
H62 FH90
Telephone: +353 (0)91 841788

Manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd
Loughrea
Co. Galway
Ireland
H62 FH90
Telephone: +353 (0)91 841788

and

Eurovet Animal Health B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

and

Labiana Life Sciences, S.A.,
C/ Venus, 26, Pol. Ind. Can Parellada, Tarrasa,
08228 Barcelona
Spain

Local representatives and contact details to report suspected adverse reactions:

Virbac Ltd
Suffolk
IP30 9UP
United Kingdom
Tel: + 44 (0) 1359 243243

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information

POM-V

Gavin Hall

Approved: 11 December 2025